首页|RNA甲基转移酶METTL3在急性髓系白血病发生发展及耐药中的研究进展

RNA甲基转移酶METTL3在急性髓系白血病发生发展及耐药中的研究进展

扫码查看
急性髓系白血病(acute myeloid leukemia,AML)是成人最常见的血液系统恶性肿瘤,其广泛的基因组变化和分子突变为药物的开发提供了潜在靶点.目前靶向治疗药物及免疫治疗无法替代传统的"3+7"方案.30%~40%的初治AML患者对于传统蒽环类方案原发耐药,治疗效果极差,是AML治疗及研究领域的重大难题.甲基转移酶样3(methyltransferase-like 3,METTL3)作为重要的甲基转移酶在调节AML发生发展及耐药中具有重要意义.本文总结了 METTL3在AML发生发展及耐药中的作用及其在抗白血病治疗中的潜力,以期为克服AML的耐药及复发提供新思路及潜在治疗靶点.
Research advances in RNA methyltransferase METTL3:occurrence,development,and drug resistance of acute myeloid leukemia
Acute myeloid leukemia(AML)is the most common haematological malignancy in adults,and its wide range of genomic changes and molecular mutations provide potential targets for drug development.However,targeted therapeutic agents and immunotherapy cannot replace the traditional"3+7"regimen.About 30%-40%of newly diagnosed AML patients are primary resistant to traditional regimens,resulting in extremely poor prognosis.Relapse and refractory after induction chemotherapy are still challenges for curing AML.Methyltransferase-like 3(METTL3),as an important methyltransferase,is important in regulating the development of AML.This article reviews the role of METTL3 in AML development and drug resistance,as well as its potential in anti-leukemia,with the aim of providing new ideas and potential therapeutic targets for overcoming drug resistance and relapse in AML.

acute myeloid leukemiaRNA methylationsN6-methyladenosinemethyltransferase-like 3drug resistance

杨晶晶、张夏玮、栾松华、窦立萍

展开 >

解放军医学院,北京 100853

解放军总医院第五医学中心血液病医学部,北京 100853

急性髓系白血病 RNA甲基化 N6-甲基腺苷 甲基转移酶样3 耐药

国家自然科学基金项目国家自然科学基金项目北京市自然科学基金项目

82270162822702247222175

2024

解放军医学院学报
解放军总医院-军医进修学院

解放军医学院学报

CSTPCD
影响因子:0.811
ISSN:2095-5227
年,卷(期):2024.45(5)